PortalPublikationenBisphosphonates and Connexin 43: A Critical Review of Eviden...

Bisphosphonates and Connexin 43: A Critical Review of Evidence

Standard

Bisphosphonates and Connexin 43: A Critical Review of Evidence. / Sadr-Eshkevari, Pooyan; Ashnagar, Sajjad; Rashad, Ashkan; Dietz, Marisa; Jackowski, Jochen; Abdulazim, Amr; Prochnow, Nora.

in: CELL COMMUN ADHES, Jahrgang 21, Nr. 5, 2014, S. 241-247.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sadr-Eshkevari, P, Ashnagar, S, Rashad, A, Dietz, M, Jackowski, J, Abdulazim, A & Prochnow, N 2014, 'Bisphosphonates and Connexin 43: A Critical Review of Evidence', CELL COMMUN ADHES, Jg. 21, Nr. 5, S. 241-247. https://doi.org/10.3109/15419061.2014.927869

APA

Sadr-Eshkevari, P., Ashnagar, S., Rashad, A., Dietz, M., Jackowski, J., Abdulazim, A., & Prochnow, N. (2014). Bisphosphonates and Connexin 43: A Critical Review of Evidence. CELL COMMUN ADHES, 21(5), 241-247. https://doi.org/10.3109/15419061.2014.927869

Vancouver

Sadr-Eshkevari P, Ashnagar S, Rashad A, Dietz M, Jackowski J, Abdulazim A et al. Bisphosphonates and Connexin 43: A Critical Review of Evidence. CELL COMMUN ADHES. 2014;21(5):241-247. https://doi.org/10.3109/15419061.2014.927869

Bibtex

@article{16c190b6ea6f400e8bf46b45e2ef4de2,
title = "Bisphosphonates and Connexin 43: A Critical Review of Evidence",
abstract = "Bisphosphonates (BPs) are drugs commonly used in the treatment of various disease arising or affecting bone tissue. There is a standard use in bone neoplasia and metastasis, hormonal and developmental disorders as well as for compensation of adverse effects in several medical therapies. Many in-vivo and in-vitro studies have assessed the efficacy of this drug and its function in cellular scale. In this concern, BPs are described to inhibit the resorptive function of osteoclasts and to prevent apoptosis of osteoblasts and osteocytes. They can preserve the osteocytic network, reduce fracture rate, and increase the bone mineral content, which is therapeutically used. Connexin 43 (Cx43) is a crucial molecule for basal regulation of bone homeostasis, development, and differentiation. It is described for signal transduction in many physiological and pathological stimuli and recently to be involved in BP action.",
author = "Pooyan Sadr-Eshkevari and Sajjad Ashnagar and Ashkan Rashad and Marisa Dietz and Jochen Jackowski and Amr Abdulazim and Nora Prochnow",
year = "2014",
doi = "10.3109/15419061.2014.927869",
language = "English",
volume = "21",
pages = "241--247",
journal = "CELL COMMUN ADHES",
issn = "1541-9061",
publisher = "informa healthcare",
number = "5",

}

RIS

TY - JOUR

T1 - Bisphosphonates and Connexin 43: A Critical Review of Evidence

AU - Sadr-Eshkevari, Pooyan

AU - Ashnagar, Sajjad

AU - Rashad, Ashkan

AU - Dietz, Marisa

AU - Jackowski, Jochen

AU - Abdulazim, Amr

AU - Prochnow, Nora

PY - 2014

Y1 - 2014

N2 - Bisphosphonates (BPs) are drugs commonly used in the treatment of various disease arising or affecting bone tissue. There is a standard use in bone neoplasia and metastasis, hormonal and developmental disorders as well as for compensation of adverse effects in several medical therapies. Many in-vivo and in-vitro studies have assessed the efficacy of this drug and its function in cellular scale. In this concern, BPs are described to inhibit the resorptive function of osteoclasts and to prevent apoptosis of osteoblasts and osteocytes. They can preserve the osteocytic network, reduce fracture rate, and increase the bone mineral content, which is therapeutically used. Connexin 43 (Cx43) is a crucial molecule for basal regulation of bone homeostasis, development, and differentiation. It is described for signal transduction in many physiological and pathological stimuli and recently to be involved in BP action.

AB - Bisphosphonates (BPs) are drugs commonly used in the treatment of various disease arising or affecting bone tissue. There is a standard use in bone neoplasia and metastasis, hormonal and developmental disorders as well as for compensation of adverse effects in several medical therapies. Many in-vivo and in-vitro studies have assessed the efficacy of this drug and its function in cellular scale. In this concern, BPs are described to inhibit the resorptive function of osteoclasts and to prevent apoptosis of osteoblasts and osteocytes. They can preserve the osteocytic network, reduce fracture rate, and increase the bone mineral content, which is therapeutically used. Connexin 43 (Cx43) is a crucial molecule for basal regulation of bone homeostasis, development, and differentiation. It is described for signal transduction in many physiological and pathological stimuli and recently to be involved in BP action.

U2 - 10.3109/15419061.2014.927869

DO - 10.3109/15419061.2014.927869

M3 - SCORING: Journal article

C2 - 24946183

VL - 21

SP - 241

EP - 247

JO - CELL COMMUN ADHES

JF - CELL COMMUN ADHES

SN - 1541-9061

IS - 5

ER -